. 2020 Jun 4;12(6):1469. doi: 10.3390/cancers12061469

Table 2.

Univariate and multivariate analyses of progression-free prognostic factors in patients with ovarian cancer.

Factors	Patients	Univariate Analysis			Multivariate Analysis
		Hazard Ratio	95% CI	p-Value	Hazard Ratio	95% CI	p-Value
Age
<65	33	0.98	0.45–2.14	0.96	NA	NA	NA
≥65	39	0.98	0.45–2.14	0.96	NA	NA	NA
Grade
G1	15	4.39	1.04–18.67	0.04	1.24	0.22–6.86	0.8
G2, G3	57	4.39	1.04–18.67	0.04	1.24	0.22–6.86	0.8
FIGO stage
I, II	44	11.57	4.53–29.68	≤0.001	7.97	2.36–26.90	0.001
III, IV	28	11.57	4.53–29.68	≤0.001	7.97	2.36–26.90	0.001
Histology
Serous	35	0.47	0.21–1.06	0.06	NA	NA	NA
Others	37	0.47	0.21–1.06	0.06	NA	NA	NA
Residual tumor
<1 cm	54	7.34	3.20–16.82	≤0.001	2.09	0.78–5.58	0.13
≥1 cm	18	7.34	3.20–16.82	≤0.001	2.09	0.78–5.58	0.13
RLT
Long	40	3.29	1.45–7.45	0.004	2.58	1.05–6.34	0.03
Short	32	3.29	1.45–7.45	0.004	2.58	1.05–6.34	0.03

CI, confidence interval; FIGO, International Freedom of Gynecology and Obstetrics; RLT, relative lymphocyte telomere length.